Abiraterone has 7 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Spironolactone, Spironolactone And Hydrochlorothiazide, Thioridazine. Patients taking Abiraterone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 7
- Contraindicated
- 3
- Major
- 2
- Moderate
- 1
- Minor
- 1
Contraindicated (3)
- Abiraterone + Spironolactone— Spironolactone binds to androgen receptor and may increase PSA levels in abiraterone-treated prostate cancer patients. C…
- Abiraterone + Spironolactone And Hydrochlorothiazide— Spironolactone binds to androgen receptor and may increase PSA levels; concomitant use is not recommended.
- Abiraterone + Thioridazine— CYP2D6 substrate with narrow therapeutic index. Avoid co-administration with abiraterone.
Major (2)
- Abiraterone + Dextromethorphan— Abiraterone increased dextromethorphan Cmax and AUC 2.8- and 2.9-fold respectively. Avoid concomitant use or consider do…
- Abiraterone + Rifampin— Strong CYP3A4 inducer decreased abiraterone exposure by 55%. Avoid concomitant use; if necessary, increase abiraterone d…
Moderate (1)
- Abiraterone + Pioglitazone— CYP2C8 substrate with AUC increased by 46% when co-administered with abiraterone. Monitor closely for toxicity signs.
Minor (1)
- Abiraterone + Ketoconazole— Strong CYP3A4 inhibitor had no clinically meaningful effect on abiraterone pharmacokinetics.